Company intelligence / Profile preview
IMMvention Therapeutix
Durham, North Carolina, United Statesimmventionthera.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
IMMvention's orally dosed BACH1 inhibitors are currently in preclinical development. They have shown potential to increase fetal hemoglobin, which is believed to ameliorate sickle cell disease pathology[6][7].
- Therapeutic areas
- CardiovascularRheumatologyNephrologyImmunologyHematologyNeurology
- Modalities
- Small molecules (oral)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Novo Nordisk A/S (strategic collaboration and license agreement announced January 22, 2025)
Beyond the preview
Go deeper on IMMvention Therapeutix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMMvention Therapeutix.